Cargando…
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression i...
Autores principales: | Ferret-Sena, Véronique, Maia e Silva, Alexandra, Sena, Armando, Cavaleiro, Inês, Vale, José, Derudas, Bruno, Chinetti-Gbaguidi, Giulia, Staels, Bart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203914/ https://www.ncbi.nlm.nih.gov/pubmed/28077943 http://dx.doi.org/10.1155/2016/5716415 |
Ejemplares similares
-
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2022) -
Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2018) -
Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages
por: Chinetti-Gbaguidi, G., et al.
Publicado: (2016) -
Serum Lipoprotein Profile Is Associated With Protective Effects of Oral Contraceptive Use on Multiple Sclerosis Severity: A Cross-Sectional Study
por: Sena, Armando, et al.
Publicado: (2019) -
PPARs/RXRs in Cardiovascular Physiology and Disease
por: Finck, Brian N., et al.
Publicado: (2008)